AMINOSYN RF INJECTION SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

ISOLEUCINE; LEUCINE; METHIONINE; PHENYLALANINE; THREONINE; TRYPTOPHAN; VALINE; LYSINE (LYSINE ACETATE); HISTIDINE; ARGININE

Pieejams no:

HOSPIRA HEALTHCARE ULC

ATĶ kods:

B05BA01

SNN (starptautisko nepatentēto nosaukumu):

AMINO ACIDS

Deva:

462MG; 726MG; 726MG; 726MG; 330MG; 165MG; 528MG; 535MG; 429MG; 600MG

Zāļu forma:

SOLUTION

Kompozīcija:

ISOLEUCINE 462MG; LEUCINE 726MG; METHIONINE 726MG; PHENYLALANINE 726MG; THREONINE 330MG; TRYPTOPHAN 165MG; VALINE 528MG; LYSINE (LYSINE ACETATE) 535MG; HISTIDINE 429MG; ARGININE 600MG

Ievadīšanas:

INTRAVENOUS

Vienības iepakojumā:

300ML

Receptes veids:

Ethical

Ārstniecības joma:

CALORIC AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 1016903001; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2016-07-29

Produkta apraksts

PRESCRIBING INFORMATION
AMINOSYN7 5%
AMINOSYN7 7%
AMINOSYN7 8.5%
AMINOSYN7 10%
AMINOSYN
TM/MD RF INJECTION 5.2%
(amino acids for injection 5%, 7%, 8.5%, 10%, and 5.2% renal formula)
SULFITE-FREE
NUTRITIVE SUPPLEMENT FOR INTRAVENOUS INFUSION
Hospira Healthcare Corporation
Date of Revision: April 11, 2012
1111 Dr. Frederik-Philips, 6
th
floor
St-Laurent,Quebec
H4M 2X6
CONTROL NOS. 150040 AND 150041
_PRESCRIBING INFORMATION; Aminosyn® 5%, 7%, 8.5%, 10% and RF
Injection 5.2% _
_Page 2 of 14 _
NAMES OF DRUGS:
AMINOSYN
7
5%
AMINOSYN
7
7%
AMINOSYN
7
8.5%
AMINOSYN
7
10%
AMINOSYN
TM/MD
RF INJECTION 5.2%
(amino acids for injection 5%, 7%, 8.5%, 10%, and 5.2% renal formula)
Sulfite-Free
THERAPEUTIC OR PHARMACOLOGICAL CLASSIFICATION
Nutritive Supplement for Intravenous Infusion
ACTION
1.
PROTEIN SPARING (PERIPHERAL USE)
:
It has been shown that it may be preferable for short periods of time,
3 to 5 days, to mobilize fat (as
in total starvation) for meeting energy requirements to spare protein.
Under conditions of total fasting, lipid mobilization provides energy
substrate in the form of free fatty
acids and ketone bodies. Lipolysis occurs because insulin levels are
low. If high concentrations of
carbohydrates are administered, insulin levels will rise and inhibit
lipid mobilization. With brief
periods of fasting (less than 24 hours), energy requirements are
usually met by glycogenolysis of the
glycogen stored in the liver. However, after glycogen is depleted,
lipolysis of body fat becomes the
fat source of energy.
Thus, when amino acids (without dextrose) are infused into a
peripheral vein, lipolysis and
ketogenesis occur freely and caloric requirements are met without
proteolysis. This spares protein
and the body's muscle mass, while providing a substrate for essential
protein synthesis.
Amino acid peripheral intravenous infusions result in: (1)
availability of free fatty acids and ketone
bodies as sources of energy, and (2) the concomitant utilization of
administered amino acids for
protein synthesis.
2.
ADJUNCTIVE FOR TO